Skip to main content
Caplight Logo









HemaCell

HemaCell

Private
SuzhouHealthcare & Life Scienceshttps://www.xuejibio.com/

Last Round

Series B

Jun 2, 2026

Total Funding Raised

$57.3M

Company Overview

HemaCell is a biotechnology company that develops stem cell-based therapeutics for the regeneration of blood cells to treat various diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cell therapyinduced pluripotent stem cellsiPSCregenerative medicineplatelet productiondrug delivery platformhematopoietic lineagebiotechbiopharmastem cell therapytargeted drug deliveryin vitro regenerationclinical-stage biotechbiotech licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

HemaCell Comparables

Compare HemaCell with similar companies based on industry and business-model similarity.

HemaCell comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
HemostOD SA
83%
Megakaryon Corporation
80%
Stellular Bio
77%

HemaCell Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 2, 2026
VC RoundJan 8, 2025
Series ADec 19, 2023
VC RoundMay 27, 2022
Pre SeedFeb 25, 2022
Seed
Oct 9, 2021

HemaCell Investors

Notable investors and investment history

HemaCell investors
InvestorRounds
Zhongbo JuliSeries A
招银国际金融有限公司Pre Seed
Wedo Venture PartnersSeries B, Pre Seed, VC Round, Seed
Northern Light Venture CapitalPre Seed, VC Round
Country Garden Ventures CapitalPre Seed, VC Round
Luxin Venture Capital GroupVC Round
Founder Hesheng Investment Co., Ltd.VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 8, 2025

    Completed a VC Round fundraise.

  • Dec 19, 2023

    Led by Zhongbo Juli with participation from CDH Investments.

HemaCell Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

HemaCell Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about HemaCell's valuation, stock price, and market status.

Firmographic Details

HeadquartersSuzhou
Year Founded2021
Last FundingJun 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?